drugset / Trial / NCT04218162
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean
RandomizedParallel-groupDouble-blindTreatment
Summary
A randomized, double-blind, placebo-controlled parallel group study to evaluate efficacy and safety of lasmiditan tablet compared to Placebo in the acute treatment of Migraine
Timeline
- Start
- 2020-03-24
- Primary completion
- 2020-10-30
- Completion
- 2020-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lasmiditan | Small molecule | 50 mg | — |
| Subject | Lasmiditan | Small molecule | 100 mg | — |